linjc16/ctgov huggingface dataset:
Survival and 30-days Hospital Outcome in COVID-19 Patients in Upper Egypt

Study Overview
=================
Brief Summary
-----------------
Through history, there have been plenty of pandemics however; the social response to corona virus disease (COVID-19) is unparalleled. It is assessed that almost four billion individuals are living in social segregation during this mother of all pandemics. Initially described in China in December 2019, severe acute respiratory syndrome caused by corona virus 2 (SARS-CoV-2) has spread all over the world and by 18th July 2020- there was an emergent figure of 13,824,739 confirmed cases and 591.666 losses reported to the WHO. To date, Egypt reported slightly over 82,000 confirmed COVID-19 cases with 3858 deaths. The new pandemic is injuring not only health organizations of several countries but also the financial prudence universal. Defining the clinical features and associated outcomes of patients diagnosed with coronavirus disease (COVID-19) is fundamental to improving our understanding and adequate management of this illness. Several articles have recently been published, describing the clinical features and outcomes of retrospective individuals with COVID-19

Official Title
-----------------
Survival and 30-days Hospital Outcome in Hospitalized COVID-19 Patients in Upper Egypt: Multi-center Study

Conditions
-----------------
Covid19, Coronavirus Disease, SARS-CoV-2

Intervention / Treatment
-----------------
* Other: Kaplan Meier analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: This study included 1064 patients consecutively admitted to isolation hospitals in Upper Egypt during the period from 22 March to 23 June 2020 Exclusion Criteria: only hospitalized confirmed cases of COVID-19 were included.

Ages Eligible for Study
-----------------
Minimum Age: 36 Years
Maximum Age: 63 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Kaplan Meier analysis|Kaplan Meier survival analysis was conducted to calculate the cumulative overall survival rates using Log Rank test for comparison between age groups|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of co-morbidities in hospitalized patients with COVID-19 | Determinants of survival in studied covid-19 patients admitted to hospitals | one month | 
| causes of ICU admission | Determinants of ICU admission in hospitalized patients with COVID-19 | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, Survival, 30- Days Hospital outcome, outcome
Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis

Study Overview
=================
Brief Summary
-----------------
Ganciclovir ophthalmic gel delivers multiple advantages in the treatment and prophylaxis of herpetic keratitis and shows potential for effectiveness against other viral ocular infections. The majority of adenoviral conjunctivitis will resolve without damaging vision, however, the investigators have no way to determine which cases will progress to ocular complications such as corneal infiltrates and pseudomembranes. Our purpose is to evaluate the efficacy of the Ganciclovir gel 0.15% in preventing ocular complications after adenoviral conjunctivitis.

Official Title
-----------------
Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis

Conditions
-----------------
Conjunctivitis, Viral, Adenoviridae Infections

Intervention / Treatment
-----------------
* Drug: Ganciclovir
* Drug: Artificial tear


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: onset of symptoms for five days or less eighteen years old or more not pregnant or breastfeeding be able to understand and sign the consent term Exclusion Criteria: use of antibiotic or corticoid 30 days before monocular vision keratopathy or other ocular diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ganciclovir<br> | Drug: Ganciclovir<br>* Ganciclovir 0.15% Ophthalmic gel<br>|
| Sham Comparator: Artificial tear<br> | Drug: Artificial tear<br>* Artificial tear 5 times per day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| improvement of symptoms of conjunctivitis (pain relief) |  | 6 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Conjunctivitis, Viral, Adenoviridae Infections, Ganciclovir, Adenovirus Keratoconjunctivitis, Treatment of viral conjunctivitis
Bipolar Versus Mono-polar Needlescopic En Bloc TUR-BT

Study Overview
=================
Brief Summary
-----------------
Non-muscle invasive bladder cancers (NMIBC) compose about 80% of bladder tumors. the stranded treatment of these tumors is TURBT. en bloc resection of NMIBC yields better mascularis propria with better oncological outcomes

Official Title
-----------------
Bipolar Versus Monopolar Needlescopic En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer: A Prospective Randomized Study

Conditions
-----------------
Bladder Cancer, Bladder Neoplasm

Intervention / Treatment
-----------------
* Procedure: Bipolar En bloc TURBT
* Procedure: Monopolar En bloc TURBT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: confirmed primary NMIBC (Ta, Tis, T1) Age > 18 years Exclusion Criteria: MIBC anterior located mass ( difficult or non visualized)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bipolar En bloc TURBT<br>patient subjected to bipolar Needlescopic En bloc resection of NMIBC | Procedure: Bipolar En bloc TURBT<br>* patients subjected to Bipolar resection of bladder tumor by Collins loop<br>|
| Active Comparator: Monopolar En bloc TURBT<br>patient subjected to Monopolar Needlescopic En bloc resection of NMIBC | Procedure: Monopolar En bloc TURBT<br>* patients subjected to Monopolar resection of bladder tumor by Collins loop (hot Knife)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of tumor Resection | presence of detrusor muscle | immediatly post operative | 
| adequacy of tumor Resection | Presence of residual tumor at the bed of previously resected NMIBC | 2 to 6 weeks postoprative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complications | Modified Clavien-Dindo classification scale | within 30 days post-operative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NMIBC, TURBT, En bloc resection
A-Mode vs PalmScan Ultrasonography: Biometric Measurements.

Study Overview
=================
Brief Summary
-----------------
Ultrasonography has become a critical ancillary test in the clinical practice of ophthalmology. It is commonly used as a standardized method for assessing intraocular biometry. The PalmScan ultrasonography (PsU) is a portable A-scan device that uses the same principles as the standard A-scan. The aim of the study is to compare the reliability of their measurements, in order to use them indistinctively.

Official Title
-----------------
Standard A-Mode Ultrasonography vs PalmScan Ultrasonography: Biometric Measurements.

Conditions
-----------------
Axial Length (AL), Anterior Chamber Deep (ACD), Lens Thickness (LT)

Intervention / Treatment
-----------------
* Device: PalmScan A2000 ultrasonography system (Micro Medical Devices, Calabasas, CA)
* Device: Standard A-mode ultrasound (Eye Cubed™, Ellex, Adelaide, Australia).


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with indication for a standard A-mode ultrasound Exclusion Criteria: No superficial anormalities. Patients with external injuries. Intraocular silicon oil. Retinal detachment Significant ocular pathologies.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>PalmScan biometric group | Device: PalmScan A2000 ultrasonography system (Micro Medical Devices, Calabasas, CA)<br>* PalmScan biometric measurements<br>|
| 2<br>A-mode ultrasonography biometric group | Device: Standard A-mode ultrasound (Eye Cubed™, Ellex, Adelaide, Australia).<br>* A-mode biometric measurements group<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| axial length (AL). |  | during examination | 
| Anterior Chamber Deep (ACD) |  | during examination | 
| Lens Thickness (LT) |  | during examination |
Symbicort Onset of Action 2

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the early onset of effect of Symbicort compared to Advair Diskus and Ventolin in adults with asthma

Official Title
-----------------
A Randomized, Multicenter, Placebo and Active-controlled, Single-dose, 4-period, Crossover Study to Evaluate the Bronchodilating Effect of SYMBICORT pMDI Versus Advair Diskus and Ventolin HFA.

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: budesonide/formoterol
* Drug: fluticasone/salmeterol
* Drug: albuterol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years of age Diagnosis of asthma and baseline lung function test results as determined by the protocol Required and received inhaled corticosteroids within timeframe and doses specified in the protocol Exclusion Criteria: Severe asthma or asthma that is markedly effected by seasonal factors Has required and received non-inhaled corticosteroids within the previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>budesonide/formoterol | Drug: budesonide/formoterol<br> <br> * Other names: Symbicort;|
| Active Comparator: 2<br>fluticasone/salmeterol | Drug: fluticasone/salmeterol<br> <br> * Other names: Advair Diskus;|
| Active Comparator: 3<br>albuterol | Drug: albuterol<br> <br> * Other names: Ventolin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FEV1 3 minutes post dose |  | 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 12 hour serial FEV1 |  | 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart) | 
| Patients perception of effect |  | Patients perception of effect | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
asthma, adults, Symbicort, budesonide/formoterol, Advair Diskus, Ventolin
Acne Treatment With Active Oplon's Patches

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to demonstrate the effect of short treatment with active OPLON patches on Acne.

Detailed Description
-----------------
Patients with Acne Vulgaris were treated overnight with active patches. Effect is observed at the end of the treatment and 24 hours later.

Official Title
-----------------
Phase II- Acne Treatment With Active Patches Which Contains Azelaic Acid, Citric Acid,Salicylic Acid and 2% Ascorbic Acid

Conditions
-----------------
Acne Vulgaris

Intervention / Treatment
-----------------
* Device: Oplon Active Patch
* Device: Placebo Patch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acne Vulgaris Over 18 years Signing informed consent Exclusion Criteria: Active treatment of acne Change in hormonal therapy Antibiotic treatment in a week prior to the experiment Sensitive skin Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Active Comparator: Oplon Active Patch<br> | Device: Oplon Active Patch<br>* Patches are placed over acne lesion overnight. Treatment is a single treatment.<br>|
| Placebo Comparator: Placebo Comparator: Placebo patch<br> | Device: Placebo Patch<br>* same as active patch<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity Score of lesion | Lesions were ranked by investigator according to severity whereas: 0-clear, 1-mild, 2-moderate, 3-sever | Severity Score of lesion [Time Frame: 24 hours following patch removal] | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity Score of lesion | Lesions were ranked by investigator according to severity whereas: 0-clear, 1-mild, 2-moderate, 3-sever | Severity Score of lesion [Time Frame: 12 hours with the patch] |
A Study of LY3857210 in Healthy Participants

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to evaluate the presence of study drug LY3857210 in the brain measured by positron emission tomography (PET) with the radioligand [18F]-LY3818850 in healthy participants. The safety and tolerability of LY3857210 will also be evaluated. The study will last up to approximately 6 weeks for each participant and may include up to four visits to the study center.

Official Title
-----------------
An Adaptive Design, Phase 1, Open-label Study to Investigate Receptor Occupancy in Brain After Single Oral Doses of LY3857210 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]-LY3818850 in Healthy Participants

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: LY3857210


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Overtly healthy male or female participants as determined by medical evaluation Have body weight ≥ 45 kilograms (kg) and body mass index (BMI) within the range 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive) Are males and in agreement to follow contraceptive requirements, or women of non-child-bearing potential Exclusion Criteria: Have contraindications to undergoing magnetic resonance imaging (MRI) examination including but not limited to implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips, and other medical implants that have not been certified for head MRI Have clinically significant findings on the screening MRI scan, as judged by the investigator Suffer from claustrophobia and would be unable to tolerate the confined spaces of MRI or PET camera

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LY3857210<br>Single doses of LY3857210 administered orally. | Drug: LY3857210<br>* Administered orally.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in brain receptor occupancy (RO) of LY3857210 measured by [18F]-LY3818850 PET scan | Change from baseline in brain RO of LY3857210 measured by [18F]-LY3818850 PET scan | Baseline through study completion, up to approximately 6 weeks |
Extracorporeal Membrane Oxygenation Effect in Prolonged Cardiopulmonary Resuscitation

Study Overview
=================
Brief Summary
-----------------
Analysis of the patients' data who were rescued with extracorporeal membrane oxygenation and without ECMO. The survival rate and the weaning rate were analyzed to see the effect of ECMO on the prolonged CPR.

Conditions
-----------------
Cardiopulmonary Resuscitation, Cardiac Arrest, Ventricular Tachycardia, Ventricular Fibrillation

Intervention / Treatment
-----------------
* Procedure: Extracorporeal membrane oxygenation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CPR > 10 min without return of spontaneous circulation Exclusion Criteria: CPR with traumatic origin unless bleeding was under control, previous irreversible brain damage, terminal status of malignancy, and the age over 75 years. For the patients with post-cardiotomy shock requiring ECLS in the operating theater because of an inability of weaning from cardiopulmonary bypass, they were excluded as well from this ECPR cohort since they did not receive cardiac massage. The patients that had signed Do-Not-Resuscitate (DNR) consent were also excluded from ECLS deployment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Extracorporeal membrane oxygenation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ECMO, CPR
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia

Study Overview
=================
Brief Summary
-----------------
This study is being done to evaluate the safety, tolerability and satisfactory relief of dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will be evaluated at 6mg twice daily and placebo.

Official Title
-----------------
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia

Conditions
-----------------
Dyspepsia

Intervention / Treatment
-----------------
* Drug: Tegaserod


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female, 18 years or older Self-reported presence of persistent or recurrent adverse digestive symptoms consistent with dyspepsia for at least 12 weeks, not necessarily consecutive, during the previous 12 months. Exclusion Criteria: Abnormal upper GI endoscopy findings such as esophageal, gastric erosions or ulcers and/or duodenal ulcers/erosions. Any of the following symptoms: heartburn, epigastric pain, nausea or vomiting. Other protocol-defined inclusion/exclusion criteria may appl

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tegaserod|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Over 6 weeks of treatment assessment of percent of days with satisfactory relief of dyspepsia and/or average severity score in (average of post-prandial fullness early satiety and bloating) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average severity score during each week. |  |  | 
| Percentage of days with satisfactory relief of dyspepsia during each week. |  |  | 
| Weekly global assessment of change in dyspepsia condition. |  |  | 
| Daily assessment of improvment of individual symptoms postprandial fullness early satiety, bloating, abdominal pain, nausea and vomiting. |  |  | 
| Quality of life at end of treatment compared to baseline. |  |  | 
| Safety and tolerability. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dyspepsia, gastrointestinal, tegaserod